Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.

CONCLUSIONS: The data indicate that the SOL regimen is effective and moderately tolerated in Chinese patients with mCRC. TRIAL REGISTRATION: CLINICAL TRIAL INFORMATION: ChiCTR-TNRC-100000838. PMID: 26739998 [PubMed - in process]
Source: Chinese Journal of Cancer - Category: Cancer & Oncology Tags: Chin J Cancer Source Type: research